Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy

Results of the pilot-phase study

Andrei Iagaru, Erik Mittra, Shahriar S. Yaghoubi, David W. Dick, Andrew Quon, Michael L. Goris, Sanjiv Sam Gambhir

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

18F-FDG PET/CT is used for detecting cancer and monitoring cancer response to therapy. However, because of the variable rates of glucose metabolism, not all cancers are identified reliably. Sodium 18as previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of 18F and 18F-FDG in a single PET/CT study for cancer detection has not been reported to date. Methods: This is a prospective pilot study (November 2007-November 2008) of 14 patients with proven malignancy (6 sarcoma, 3 prostate cancer, 2 breast cancer, 1 colon cancer, 1 lung cancer, and 1 malignant paraganglioma) who underwent separate 18F PET/CT and 18F-FDG PET/CT and combined 18F/ 18F-FDG PET/CT scans for the evaluation of malignancy (a total of 3 scans each). There were 11 men and 3 women (age range, 19-75 y; average, 50.4 y). Results: Interpretation of the combined 18F/ 18F-FDG PET/CT scans compared favorably with that of the 18F-FDG PET/CT (no lesions missed) and the 18F PET/CT scans (only 1 skull lesion seen on an 18F PET/CT scan was missed on the corresponding combined scan). Through image processing, the combined 18F/ 18F-FDG scan yielded results for bone radiotracer uptake comparable to those of the 18F PET/CT scan performed separately. Conclusion: Our pilot-phase prospective trial demonstrates that the combined 18F/ 18F-FDG administration followed by a single PET/CT scan is feasible for cancer detection. This combined method opens the possibility for improved patient care and reduction in health care costs. COPYRIGHT

Original languageEnglish (US)
Pages (from-to)501-505
Number of pages5
JournalJournal of Nuclear Medicine
Volume50
Issue number4
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Fluorides
Neoplasms
Colonic Neoplasms
Lung Neoplasms
Breast Neoplasms
Bone and Bones
Paraganglioma
Positron Emission Tomography Computed Tomography
Skull
Sarcoma
Health Care Costs
Prostatic Neoplasms
Patient Care
Sodium
Prospective Studies
Glucose

Keywords

  • F
  • F-FDG
  • malignancy
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy : Results of the pilot-phase study. / Iagaru, Andrei; Mittra, Erik; Yaghoubi, Shahriar S.; Dick, David W.; Quon, Andrew; Goris, Michael L.; Gambhir, Sanjiv Sam.

In: Journal of Nuclear Medicine, Vol. 50, No. 4, 01.04.2009, p. 501-505.

Research output: Contribution to journalArticle

Iagaru, Andrei ; Mittra, Erik ; Yaghoubi, Shahriar S. ; Dick, David W. ; Quon, Andrew ; Goris, Michael L. ; Gambhir, Sanjiv Sam. / Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy : Results of the pilot-phase study. In: Journal of Nuclear Medicine. 2009 ; Vol. 50, No. 4. pp. 501-505.
@article{f7a1e5a74c974a86be80b6f4a1077111,
title = "Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: Results of the pilot-phase study",
abstract = "18F-FDG PET/CT is used for detecting cancer and monitoring cancer response to therapy. However, because of the variable rates of glucose metabolism, not all cancers are identified reliably. Sodium 18as previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of 18F and 18F-FDG in a single PET/CT study for cancer detection has not been reported to date. Methods: This is a prospective pilot study (November 2007-November 2008) of 14 patients with proven malignancy (6 sarcoma, 3 prostate cancer, 2 breast cancer, 1 colon cancer, 1 lung cancer, and 1 malignant paraganglioma) who underwent separate 18F PET/CT and 18F-FDG PET/CT and combined 18F/ 18F-FDG PET/CT scans for the evaluation of malignancy (a total of 3 scans each). There were 11 men and 3 women (age range, 19-75 y; average, 50.4 y). Results: Interpretation of the combined 18F/ 18F-FDG PET/CT scans compared favorably with that of the 18F-FDG PET/CT (no lesions missed) and the 18F PET/CT scans (only 1 skull lesion seen on an 18F PET/CT scan was missed on the corresponding combined scan). Through image processing, the combined 18F/ 18F-FDG scan yielded results for bone radiotracer uptake comparable to those of the 18F PET/CT scan performed separately. Conclusion: Our pilot-phase prospective trial demonstrates that the combined 18F/ 18F-FDG administration followed by a single PET/CT scan is feasible for cancer detection. This combined method opens the possibility for improved patient care and reduction in health care costs. COPYRIGHT",
keywords = "F, F-FDG, malignancy, PET/CT",
author = "Andrei Iagaru and Erik Mittra and Yaghoubi, {Shahriar S.} and Dick, {David W.} and Andrew Quon and Goris, {Michael L.} and Gambhir, {Sanjiv Sam}",
year = "2009",
month = "4",
day = "1",
doi = "10.2967/jnumed.108.058339",
language = "English (US)",
volume = "50",
pages = "501--505",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy

T2 - Results of the pilot-phase study

AU - Iagaru, Andrei

AU - Mittra, Erik

AU - Yaghoubi, Shahriar S.

AU - Dick, David W.

AU - Quon, Andrew

AU - Goris, Michael L.

AU - Gambhir, Sanjiv Sam

PY - 2009/4/1

Y1 - 2009/4/1

N2 - 18F-FDG PET/CT is used for detecting cancer and monitoring cancer response to therapy. However, because of the variable rates of glucose metabolism, not all cancers are identified reliably. Sodium 18as previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of 18F and 18F-FDG in a single PET/CT study for cancer detection has not been reported to date. Methods: This is a prospective pilot study (November 2007-November 2008) of 14 patients with proven malignancy (6 sarcoma, 3 prostate cancer, 2 breast cancer, 1 colon cancer, 1 lung cancer, and 1 malignant paraganglioma) who underwent separate 18F PET/CT and 18F-FDG PET/CT and combined 18F/ 18F-FDG PET/CT scans for the evaluation of malignancy (a total of 3 scans each). There were 11 men and 3 women (age range, 19-75 y; average, 50.4 y). Results: Interpretation of the combined 18F/ 18F-FDG PET/CT scans compared favorably with that of the 18F-FDG PET/CT (no lesions missed) and the 18F PET/CT scans (only 1 skull lesion seen on an 18F PET/CT scan was missed on the corresponding combined scan). Through image processing, the combined 18F/ 18F-FDG scan yielded results for bone radiotracer uptake comparable to those of the 18F PET/CT scan performed separately. Conclusion: Our pilot-phase prospective trial demonstrates that the combined 18F/ 18F-FDG administration followed by a single PET/CT scan is feasible for cancer detection. This combined method opens the possibility for improved patient care and reduction in health care costs. COPYRIGHT

AB - 18F-FDG PET/CT is used for detecting cancer and monitoring cancer response to therapy. However, because of the variable rates of glucose metabolism, not all cancers are identified reliably. Sodium 18as previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of 18F and 18F-FDG in a single PET/CT study for cancer detection has not been reported to date. Methods: This is a prospective pilot study (November 2007-November 2008) of 14 patients with proven malignancy (6 sarcoma, 3 prostate cancer, 2 breast cancer, 1 colon cancer, 1 lung cancer, and 1 malignant paraganglioma) who underwent separate 18F PET/CT and 18F-FDG PET/CT and combined 18F/ 18F-FDG PET/CT scans for the evaluation of malignancy (a total of 3 scans each). There were 11 men and 3 women (age range, 19-75 y; average, 50.4 y). Results: Interpretation of the combined 18F/ 18F-FDG PET/CT scans compared favorably with that of the 18F-FDG PET/CT (no lesions missed) and the 18F PET/CT scans (only 1 skull lesion seen on an 18F PET/CT scan was missed on the corresponding combined scan). Through image processing, the combined 18F/ 18F-FDG scan yielded results for bone radiotracer uptake comparable to those of the 18F PET/CT scan performed separately. Conclusion: Our pilot-phase prospective trial demonstrates that the combined 18F/ 18F-FDG administration followed by a single PET/CT scan is feasible for cancer detection. This combined method opens the possibility for improved patient care and reduction in health care costs. COPYRIGHT

KW - F

KW - F-FDG

KW - malignancy

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=63849107018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849107018&partnerID=8YFLogxK

U2 - 10.2967/jnumed.108.058339

DO - 10.2967/jnumed.108.058339

M3 - Article

VL - 50

SP - 501

EP - 505

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -